What is Altimmune Inc?
, a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 258.80M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 460,700 shares $96k |
| 3-6months | 0 | 115,000 shares $44k |
| 6-9months | 0 | 559,200 shares $198k |
| 9-12months | 0 | 531,027 shares $127k |